Borchardt PE - Search Results

1

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G. Ballangrud AM, et al. Among authors: borchardt pe. Clin Cancer Res. 2004 Jul 1;10(13):4489-97. doi: 10.1158/1078-0432.CCR-03-0800. Clin Cancer Res. 2004. PMID: 15240541

2

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA. Miederer M, et al. Clin Cancer Res. 2004 Oct 15;10(20):6985-92. doi: 10.1158/1078-0432.CCR-04-0859. Clin Cancer Res. 2004. PMID: 15501978

3

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Borchardt PE, et al. Cancer Res. 2003 Aug 15;63(16):5084-90. Cancer Res. 2003. PMID: 12941838

4

Tumor therapy with targeted atomic nanogenerators.

McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. McDevitt MR, et al. Science. 2001 Nov 16;294(5546):1537-40. doi: 10.1126/science.1064126. Science. 2001. PMID: 11711678

5

Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.

Vriesendorp HM, Quadri SM, Wyllie CT, Lai J, Borchardt PE, Harris L, Wucher R, Askew E, Schweichler L. Vriesendorp HM, et al. Among authors: borchardt pe. Clin Cancer Res. 1999 Oct;5(10 Suppl):3324s-3329s. Clin Cancer Res. 1999. PMID: 10541381

6

Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.

Lai J, Quadri SM, Borchardt PE, Harris L, Wucher R, Askew E, Schweichel L, Vriesendorp HM. Lai J, et al. Among authors: borchardt pe. Clin Cancer Res. 1999 Oct;5(10 Suppl):3315s-3323s. Clin Cancer Res. 1999. PMID: 10541380

7

Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.

Borchardt PE, Vriesendorp HM, Freedman RS, Quadri SM. Borchardt PE, et al. Cancer Biother Radiopharm. 2004 Feb;19(1):43-51. doi: 10.1089/108497804773391667. Cancer Biother Radiopharm. 2004. PMID: 15068610

8

Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis.

Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Borchardt PE, et al. Cancer Biother Radiopharm. 2000 Feb;15(1):53-64. doi: 10.1089/cbr.2000.15.53. Cancer Biother Radiopharm. 2000. PMID: 10740653

9

Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.

Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Borchardt PE, et al. J Nucl Med. 1998 Mar;39(3):476-84. J Nucl Med. 1998. PMID: 9529295 Free article.

10

Intralesional radiolabeled human monoclonal IgM in human tumor xenografts.

Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Borchardt PE, et al. Radiother Oncol. 1997 Sep;44(3):283-93. doi: 10.1016/s0167-8140(97)00129-1. Radiother Oncol. 1997. PMID: 9380829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters